* Alexion Pharmaceuticals Inc., of New Haven, Conn.,said its complement inhibitor monoclonal antibody waseffective in two different animal models ofglomerulonephritis, a form of kidney inflammationassociated with lupus.
* Genentech Inc., of South San Francisco, said its non-Roche shareholders approved the transaction that extendsfor four year's Switzerland-based Roche Holding Ltd.'soption to have Genentech redeem the outstanding stockof the company, and provides for shareholders to put theirshares to Genentech at $60 per share for 30 daysfollowing the close of the option period.
* IMRE Corp., of Seattle, said results of a 15-patient trialof the Prosorba column showed a statistically significant59 percent reduction in painful joints and 60 percentreduction in swollen joints at the six-month follow-upperiod.
* Orphan Medical Inc., of Minneapolis, submitted a newdrug application to the FDA for Cystadane, or betaineanhydrous powder, to treat homocystinuria. Betaine is anaturally occurring substance thought to reducehomocysteine levels in the blood. Elevated amounts ofhomocysteine cause the rare, genetic disorder, which islinked to a number of complications, such as mentalretardation, skeletal abnormalities and seizure disorders.
* RiboGene Inc., of Hayward, Calif., was awarded asmall business innovation research Phase II grant up to$750,000 to develop drugs for fungal infections.
* Synsorb Biotech Corp., of Calgary, Alberta, wasgranted orphan drug status from the FDA for its product,Synsorb Pk, to treat Escherichia coli infections.
* Pharmos Corp., of Alachua, Fla., said results werepresented showing the neuroprotective activity of the HU-211 in rats subjected to temporary focal forebrainischemia. The neurological outcome of the ischemia wassignificantly improved in the drug group compared tovehicle. The drug already has completed Phase I studiesin humans.
(c) 1997 American Health Consultants. All rights reserved.